X4 Pharmaceuticals combines a perfect four-quarter earnings-beat streak with a deeply favorable asymmetry ratio and 187% analyst upside, but persistent insider selling and extreme cash burn against a Rule-of-40 failure keep the underlying quality score below the platform's investable floor.
Thesis pillars
- Massive Analyst Upside And Asymmetry↓Deteriorating
- Perfect Earnings Beat Streak→Stable
- Insider Selling Despite Bull Signals→Stable
- +1 more pillar — see the Why tab for full reasoning
X4 Pharmaceuticals, Inc. (XFOR) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $3.01, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: mavorixafor; Concentration risk — Product: XOLREMDI (mavorixafor).
X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare hematology diseases, built around a single small-molecule asset, mavorixafor, an oral CXCR4 antagonist. Its only approved product, XOLREMDI, has FDA accelerated approval for WHIM syndrome, while... Read more
Hold if already holding. Not a fresh buy at $3.01, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: mavorixafor; Concentration risk — Product: XOLREMDI (mavorixafor). Chart setup: Oversold RSI 22, near Bollinger lower, volume surge. Market cap $298M below $400M minimum. Not in investable universe. Score 4.9/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 40d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About X4 Pharmaceuticals, Inc.
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals advances mavorixafor, an oral CXCR4 antagonist, through a global Phase 3 trial (4WARD) targeting chronic neutropenia, while its only approved product, XOLREMDI, holds FDA accelerated approval for WHIM syndrome in patients 12 and older. The company held $253.0 million in cash, cash equivalents, and marketable securities as of December 31, 2025, funded by an $81.0 million August 2025 private placement and a $145.6 million fourth-quarter public offering.
X4 licenses its foundational CXCR4 intellectual property from Genzyme Corporation, a Sanofi subsidiary, under a 2014 agreement requiring milestone payments and tiered royalties of 6% to 12% on annual net sales of mavorixafor, plus a share of sublicense revenue. X4 sublicensed European, Australian, and New Zealand rights to Norgine Pharma UK in January 2025 for an upfront €28.5 million, up to €226.0 million in regulatory and sales milestones, and royalties reaching the mid-twenties percent; additional territory-specific deals cover the Middle East and North Africa (Taiba rare) and Greater China (Abbisko Therapeutics). Manufacturing relies on third-party contractors: Evotec A.G. produces the mavorixafor active pharmaceutical ingredient, and Catalent Inc. is X4's sole manufacturer of the finished capsule drug product. In the U.S., XOLREMDI reaches WHIM syndrome patients through a specialty pharmacy channel rather than an actively promoted commercial sales force.
Show full overview
X4 concentrates critical-path manufacturing risk in two named contractors: Catalent Inc. is described in the filing as the company's sole manufacturer of the finished mavorixafor capsule, and Evotec A.G. supplies the active pharmaceutical ingredient under a dedicated commercial supply agreement. The 10-K states X4 has no in-house manufacturing facility and limited experience manufacturing its product candidates at large clinical or commercial scale, meaning a disruption at either contractor could delay 4WARD trial supply or XOLREMDI commercial availability. The company similarly depends on third-party contract research organizations to run the 4WARD trial across more than 100 planned clinical sites.
See also: Healthcare · Biotechnology
From X4 Pharmaceuticals, Inc.'s most recent 10-K filing, extracted August 23, 2026.
Recent developments
updated 2026-09-26Recent Developments — X4 Pharmaceuticals, Inc.
Latest news
- NEWS X4 Pharmaceuticals Says FDA Agreed To Reduce Phase 3 4WARD Chronic Neutropenia Trial Size From 176 To 126 Participants; — benzinga Sep 8, 2026
- NEWS FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat Congenital — benzinga Aug 26, 2026 positive
- NEWS Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session — benzinga Aug 10, 2026 neutral
Generated 2026-09-26T22:51:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHpipelinemavorixafor10-K Item 1A: 'We depend almost entirely on the success of our future product candidate, mavorixafor.'
- HIGHProductXOLREMDI (mavorixafor)10-K Item 1: 'We have one commercially approved product, XOLREMDI® (mavorixafor), which has received accelerated approval in the United States from the FDA'
- HIGHSupplierCatalent10-K Item 1: 'master services agreement in place with Catalent Inc. ... which is our sole manufacturer for the final capsule drug product formulation'
Material Events(8-K, last 90d)
- 2026-07-01Item 5.02LOWKelly Gold appointed Class II director effective July 1, 2026, expanding the board from five to six members and joining the Audit Committee. Ms. Gold is CFO of CAMP4 Therapeutics; routine board appointment, no departure involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $3.01, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: mavorixafor; Concentration risk — Product: XOLREMDI (mavorixafor). Chart setup: Oversold RSI 22, near Bollinger lower, volume surge. Market cap $298M below $400M minimum. Not in investable universe. Target $4.15 (+37.9%), stop $2.87 (−4.9%), A.R:R 0.0:1. Score 4.9/10, moderate confidence.
Take-profit target: $4.15 (+37.9% upside). Target $4.15 (+37.9%), stop $2.87 (−4.9%), A.R:R 0.0:1. Stop-loss: $2.87.
Concentration risk — Pipeline: mavorixafor; Concentration risk — Product: XOLREMDI (mavorixafor); DATA_ISSUE: analyst_target_implausible (raw $11.60 vs price $3.01 — ratio 3.9×). Rejected, falling back to technical TP..
X4 Pharmaceuticals, Inc. trades at a P/E of 2.2 (forward -3.9). TrendMatrix value score: 5.0/10. Verdict: Hold.
11 analysts cover XFOR with a consensus score of 4.4/5. Average price target: $12.
What does X4 Pharmaceuticals, Inc. do?X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare hematology diseases, built around a...
X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare hematology diseases, built around a single small-molecule asset, mavorixafor, an oral CXCR4 antagonist. Its only approved product, XOLREMDI, has FDA accelerated approval for WHIM syndrome, while the company depends almost entirely on mavorixafor succeeding in a global Phase 3 trial (4WARD) for chronic neutropenia, funded by $253.0 million in cash and securities as of December 31, 2025.